The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology

Eur Heart J. 2000 Aug;21(15):1216-31. doi: 10.1053/euhj.2000.2249.
No abstract available

Publication types

  • Consensus Development Conference
  • Review

MeSH terms

  • Action Potentials / drug effects
  • Animals
  • Anti-Arrhythmia Agents / adverse effects
  • Anti-Inflammatory Agents / adverse effects*
  • Antipsychotic Agents / adverse effects*
  • Cardiology
  • Drug Approval / legislation & jurisprudence
  • Electrocardiography / drug effects*
  • Europe
  • Humans
  • Long QT Syndrome / chemically induced*
  • Long QT Syndrome / physiopathology
  • Long QT Syndrome / prevention & control
  • Myocardium / metabolism
  • Policy Making*
  • Practice Guidelines as Topic*
  • Societies, Medical
  • Vasodilator Agents / adverse effects*

Substances

  • Anti-Arrhythmia Agents
  • Anti-Inflammatory Agents
  • Antipsychotic Agents
  • Vasodilator Agents